Skip to main content
Equibles
LAB logo

LAB · Standard Biotools Inc. · Metrics

Track LAB — free

Use LAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.61 -0.03 (-4.72%) At close · Oct 23
Rebalance outlook locked
Market Cap
$237.75M
Shares
392.58M
Volume · Oct 23 853K Avg daily vol (3M) 1.36M

LAB metrics

87 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.61
Market cap
$237.75M

Price action

20 metrics
Price change (1W)
-3.7%
Price change (30D)
-18.2%
Price change (3M)
-27.0%
Price change (6M)
-32.7%
Price change (YTD)
-52.7%
Price change (1Y)
-56.1%
Trailing year
Price change (5Y)
-88.4%
52-week high
$1.68
52-week low
$0.61
Change from 52-week high
-64.0%
Change from 52-week low
+0.0%
Annualized volatility
69.2%
Annualized volatility (3M)
54.8%
Beta
1.1
RSI (14D)
35.7
Price vs SMA 50
-11.8%
Price vs SMA 200
-35.5%
Avg volume (3M)
1.36M
Relative volume
0.6
Average dollar volume
$988,293

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
392.58M

Valuation

12 metrics
P / E (TTM)
2.8
Trailing earnings · reciprocal yield 36.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.6%
P / book
0.4
reciprocal yield 227.1%
FCF yield
-34.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
35.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.8×
reciprocal yield 35.7%
EV / revenue historical average (5Y)
2.8×
reciprocal yield 35.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-08-11

Profitability

9 metrics
Gross margin
50.5%
Operating margin
-112.8%
Trailing 12 months
Net margin
100.4%
Gross profit (TTM)
$42.71M
Operating profit (TTM)
−$95.47M
Net income (TTM)
$84.91M
Trailing 12 months
Diluted EPS (TTM)
$0.22
FCF margin
-97.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.22
Gross profit per diluted share (TTM)
$0.11
Operating profit per diluted share (TTM)
$-0.25
EBITDA per diluted share (TTM)
$-0.23
Net income per diluted share (TTM)
$0.22
Operating cash flow per diluted share (TTM)
$-0.21
Free cash flow per diluted share (TTM)
$-0.21
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.05
Stock compensation per diluted share (TTM)
$0.07
Book value per share
$1.44

Growth

11 metrics
Revenue growth YoY
-7.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$84.60M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.7%
Year over year · more shares
Revenue CAGR (3Y)
-4.5%
Revenue CAGR (5Y)
-9.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.7%
Return on assets
13.5%
Debt / equity
—
Current ratio
9.1
EBITDA (TTM)
−$89.97M
Free cash flow (TTM)
−$82.58M
Quick ratio
8.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$270.03M
Total assets
$627.22M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$80.30M
Capital expenditures (TTM)
$2.28M
R&D (TTM)
$18.42M
SG&A (TTM)
$86.93M
Stock compensation (TTM)
$27.09M
R&D / revenue
21.8%
Stock compensation / revenue
32.0%

Ownership (13F)

9 metrics
13F filers
143
13F filer change QoQ
-13
Institutional ownership
75.5%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
61.1%
Private-fund adviser ownership
59.4%
Active holders' share change QoQ
+12.9%
Holder tenure
10.0
Price vs estimated holder cost
-55.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.9%

Short interest

3 metrics
Short interest
0.6%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1162194 CUSIP 34385P108 13F (30d) 5 filings 5 filers Visit website Investor relations